Sino Biological, Inc. has announced the launch of its XPressMAX™ Cell-Free Protein Synthesis Kit (Cat#: CFKIT02), a novel tool designed to accelerate artificial intelligence (AI)-powered high-throughput screening for antibody drug discovery. The kit, which leverages advanced cell-free protein synthesis technology, enables rapid in vitro production of target proteins and antibodies without the constraints of traditional cell-based expression systems. According to the company, the new offering integrates seamlessly with AI screening platforms to dramatically reduce development timelines and costs.
The XPressMAX™ kit is based on an E. coli lysate fully supplemented with essential transcription and translation components, allowing direct protein synthesis from plasmid or PCR templates. Specifically designed for antibody discovery, it supports rapid expression and validation of VHH, scFv, Fab, and miniproteins. Sino Biological has established a high-throughput cell-free expression platform using XPressMAX™ that can validate over 2,000 scFv/VHH molecules in 3-4 weeks, matching AI’s rapid iteration capabilities.
Key highlights of the kit include ultra-fast synthesis completed in just 3 hours, a success rate greater than 99%, and support for complex disulfide bonding resulting in native folding and bioactivity without additional enhancers. “Our XPressMAX™ is a significant advancement in research tools and reagents for next-generation therapeutic discovery,” said Dr. Rob Burgess, Chief Business Officer at Sino Biological US, Inc. “By combining rapid, reliable protein expression with intelligent screening, we are helping our partners compress antibody discovery timelines without compromising quality.”
Dr. Jie Zhang, Sino Biological’s General Manager, added, “AI is revolutionizing antibody screening, but it demands expression systems that can match its speed and throughput. XPressMAX™ achieves rapid, high-success expression of challenging proteins in as little as 3 hours.” Researchers can visit www.sinobiological.com to explore more about XPressMAX™ or request a free sample via the online form.
The launch of XPressMAX™ comes at a time when AI-driven drug discovery is increasingly reliant on high-quality protein expression systems that can keep pace with computational screening. By enabling rapid synthesis of correctly folded, bioactive proteins, the kit addresses a critical bottleneck in the antibody development pipeline. This innovation is particularly relevant for the development of next-generation therapeutics, where speed and accuracy are paramount.
Sino Biological, an international reagent supplier and CRO service provider, specializes in recombinant protein production and antibody development. With the US-based Center for Bioprocessing (C4B) in Houston and SignalChem Biotech in Canada, the company delivers tailored, localized solutions to diverse research needs worldwide.
